SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Biotech Bay
Money on the Move: July 7 – 13
More biopharma companies race toward the Nasdaq this week, while a few rake in cash via private funding rounds.
July 14, 2021
 · 
4 min read
 · 
Kate Goodwin
Andia/Universal Images Group via Getty Images
Business
China’s CRISPR Babies Propel WHO to Issue Global Standards for Gene Editing
The WHO panel recommends adopting global standards, giving structure to prevent the unscrupulous, inequitable, and possibly dangerous uses of CRISPR technology.
July 13, 2021
 · 
3 min read
 · 
Kate Goodwin
Yuriko Nakao/Getty Images
Drug Development
Galapagos Touts Positive Post-Hoc Data, but Likely Won’t Gun for US Approval
While the drug showed significant improvement in patients on a 200mg daily dose of filgotinib, it may not be promoted in the states any time soon.
July 12, 2021
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Ovid Realigns C-Suite After Throwing in the Towel on Phase III Candidate
This week’s announcement includes a step to the side for CMO Amit Rakhit, who will transition to the biotech’s advisory board.
July 9, 2021
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Getty Images
Business
Lilly Fronts $25 Million to Use Verge’s AI Discovery for New ALS Drug Candidates
Startups have passion and big, bold ideas. Pharma has the funds and human resources. Together, they can change the future of medicine.
July 8, 2021
 · 
2 min read
 · 
Kate Goodwin
Maddie Meyer/Getty Images
Genetown
Will Moderna’s mRNA Flu Vaccine Walk a Golden Road?
The vaccine, mRNA-1010, targets lineages recommended by the World Health Organization.
July 7, 2021
 · 
3 min read
 · 
Kate Goodwin
BioCapital
Money on the Move: June 30 – July 6
The long weekend didn’t slow down the IPO train barreling down the tracks. More life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
July 7, 2021
 · 
6 min read
 · 
Kate Goodwin
Alexi Rosenfeld/Getty Images
Deals
Let Freedom Ring on the NASDAQ – Four Companies File for IPOs
Tossing their names in the hat just before long weekend, four life sciences companies filed for $100 million IPOs Friday afternoon.
July 6, 2021
 · 
4 min read
 · 
Kate Goodwin
Drug Development
Pardes Goes from Stealth to SPAC in Less than Two Years with COVID-19 Pill
The COVID-19 pandemic has led to faster R&D, faster approvals, faster science than ever before. It’s even leading to faster company development.
June 30, 2021
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Lifetime of Protection Against COVID-19 May Be Possible with mRNA Vaccines
A new study published in Nature offers good news for those who recovered from COVID-19 and were then vaccinated with a mRNA vaccine – a booster may not be needed.
June 29, 2021
 · 
2 min read
 · 
Kate Goodwin
Pharm Country
How a New Class of Cancer Drug Could Stop Future Coronaviruses
A new class of compounds currently in development against acute myeloid leukemia has been discovered to block coronavirus reproduction in human lung cells.
June 25, 2021
 · 
2 min read
 · 
Kate Goodwin
BioForest
COVID-19 Origin Story Plot Thickens as Researcher Unearths Deleted Early Virus Sequences
Last summer, claims that the deadly SARS-CoV-2 virus emerged from a virology lab in Wuhan were generally dismissed by the scientific community as right-wing conspiracy theories. A year later, the theory isn’t sounding so far-fetched.
June 24, 2021
 · 
5 min read
 · 
Kate Goodwin
Business
Money on the Move: June 16 – 22
Life sciences advances continue to be an exciting opportunity for investors. Here’s a glance at the companies attracting fresh funding the past week.
June 23, 2021
 · 
5 min read
 · 
Kate Goodwin
Policy
Customs Officers Seize Illicit Remdesivir Treatments Bound for Mexico
Crisis has a way of opening doors of opportunity for fraud around the globe. The COVID-19 pandemic has brought not only a fresh slew of financial schemes, but pharmaceutical fraud as well.
June 23, 2021
 · 
3 min read
 · 
Kate Goodwin
Chris Guiffre, CFO and COO of Pear.
FDA
Pear Picks SPAC Merger to Grow Prescription Digital Therapeutics Platform
By merging with New Haven’s SPAC Thimble Point Acquisition Corp., Pear will be valued at $1.6 billion.
June 22, 2021
 · 
3 min read
 · 
Kate Goodwin
Load More